Treinta y seis patentes en todo el mundo de una nueva invención británica que destruye el virus de la influenza porcina en minutos

Científicos británicos han desarrollado un purificador de aire único, patentado ahora en 36 jurisdicciones en todo el mundo, la que, de acuerdo con investigaciones independientes, puede matar a los virus de la gripe porcina H1N1 y de la gripe aviar H5N1 en cuestión de minutos en cualquier habitación u otro espacio cerrado. También es efectivo contra el “super bicho” Staphylococcus aureus resistente a la meticilina y otros virus y bacterias transportados por el aire.
La tecnología no consiste en un proceso de filtración: la unidad solo combina tres diferentes métodos de decontaminación para simular las propiedades naturales de purificación del aire fresco, creando los radicales hydroxyl de limpieza que aparecen al aire libre. La tecnología “restriega” el aire limpio de virus y bacterias que son propagados por el aire y también es efectiva contra aquellos sobre superficies –lo que podría ayudar a proteger contra infecciones adquiridas en los hospitales, oficinas hermetizadas, casas y espacios públicos del virus de la influenza.

http://www.medicalnewstoday.com/articles/154192.php

The technology has been tested by the UK’s Health Protection Agency for its ability to kill both airborne and surface bacteria and viruses, and was shown to be 99.999 per cent effective in killing an airborne test Staphylococcus of the same genus as MRSA in less than two minutes. It significantly reduces airborne spores similar to C. difficile in one hour (reference: UK HPA Centre for Emergency Preparedness and Response, Porton Down, Sep 24, 2007).

Air Purifier Technology

The Tri-Air Developments unit replicates the conditions of the natural outdoor purification process, rich in hydroxyl radicals, which easily destroy microbes including H5N1, H1N1, other flu and cold viruses as well as bacteria, both in the air and on surface contact. Hydroxyl radicals are found naturally in abundance in outdoor fresh air, with high concentrations in forested mountain areas.

The UK patent was granted in May 2007, and Tri-Air now has 36 jurisdictions in April 2009 patented around the world with others pending, along with a number of additional patents filed.

The biotechnology unit uniquely combines three established decontamination technologies to overcome their inherent individual shortcomings, says Gideon Davenport, CEO of Tri-Air Developments: non-thermal plasma; ultraviolet catalysis; and OAF (Open Air Factor). This creates a fresh air environment that is lethal to viruses and bacteria, including Flu viruses and MRSA, and continually decontaminates by a process of advanced oxidation.

The decontamination process occurs both within and outside the machine, to create a continual supply of hydroxyl radicals dispersed throughout a room, making it effective even without processing all of the air through the unit. This process is 100 times more effective than current methods of decontamination, according to inventors Tri-Air Developments – co-founded by the UK’s BRE (Building Research Establishment), microbiologists at Promanade Ltd and technology transfer specialists Inventa Partners Ltd.

The technology can be adapted for a range of applications, such as within large ventilation systems for a commercial office or airport, or for portable use in a single hospital ward or room, or even for use in the home. Tri-Air, along with retained commercial advisors PricewaterhouseCoopers, has licence discussions under way with a shortlist of international manufacturing companies in North America, Europe and Asia to structure rights for production in a number of these industry sectors.